Replies to post #5825 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jp2011, you are correct that it may be for a competitor.

However, if unlike the cancer drug it did not have a target action date and Dexcel was leading the approval process, Ani could have chose to wait until it was approved knowing the FDA can throw additional request pushing timeline back.

Teva and Sandoz had launched it 2010.

Joint Launch

Teva ran into manufacturing problems in 2011 and withdrew the drug accordingly.

Drug Withdrawal


The 2014 IMS Market of $220 million.